Insmed upgraded at JMP Securities

theflyonthewall.com

As noted earlier, JMP Securities upgraded Insmed to Outperform from Market Perform with a $25 price target. The firm thinks there is a good chance that data expected to be relapsed in March on the company's non-tuberculosis mycobacteria treatment will be positive.

View Comments (0)